Alvotech announced pricing and allocation of a $152 million public share offering in the US and a concurrent private placement in Europe at $3.75 per share. The company expects total proceeds up to $165 million if underwriters exercise their full option. Funds will support development of biosimilar drugs, operational costs, and debt refinancing. The US offering is expected to close by June 17, and the European placement by June 25, 2026.
Alvotech announced a $152 million public offering and concurrent private placement of ordinary shares priced at $3.75 each. The public offering includes 22.7 million shares, with an option for underwriters to buy an additional 3.4 million shares. The...
The Schall Law Firm has launched an investigation into Oxford Industries following the company's sharp revenue guidance cut on June 10, 2026, which caused a significant drop in its share price. The probe focuses on whether Oxford issued false or misl...
The global market for highway, street, and bridge construction is projected to grow from $1.28 trillion in 2025 to $2.18 trillion by 2035, at a compound annual growth rate of 4.8%. Growth is driven by government infrastructure spending, urbanization,...
Pepeto's presale has rapidly raised over $10.27 million as Bitcoin's price surges past $66,600, fueled by positive market events like the US-Iran ceasefire and renewed ETF inflows. Cathie Wood's bullish Bitcoin price prediction of $1.25 million by 20...
Alibaba is reportedly offering $1.5 billion to acquire Pupu, a dominant online grocer in South China's Fujian province, more than double the $717 million Meituan paid for Dingdong, a national online grocer. This move highlights the fierce competition...
